Alaunos Therapeutics (TCRT) falls on cash concerns, Nasdaq delisting risk
Alaunos Therapeutics shares are looking weak going into Friday in the U.S. after dropping 6.9% to finish Thursday at $2.44. Investors are watching the company's slim cash levels and its early-stage obesity drug program. The stock is listed on the Nasdaq Capital Market, with Friday’s session set for normal trading hours. Alaunos is a small biotech, with a market cap near $6 million at Thursday’s close. The shares have moved between $1.67 and $6.20 in the last 52 weeks. The thin trading leaves the stock open to quick swings.